Latest News - Zimmer Biomet
Top Corporates Hub
Zimmer Biomet
Major Players Like Zimmer Biomet and Stryker Drive Cranio Maxillofacial Fixation Devices Market Growth
15.12.2025 09:04
The cranio maxillofacial fixation devices market offers growth opportunities driven by rising facial trauma cases and technological advancements like 3D-printed implants. Increasing cosmetic surgeries and improved healthcare access in emerging markets further fuel demand. North America leads, with notable player participation.Dublin, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The "Cranio Maxillofacial Fixation (CMF) Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032" has been ad
Zimmer Biomet (ZBH): Assessing Valuation After a Year of Weak Share Price Performance
03.12.2025 04:25
Zimmer Biomet Holdings (ZBH) has been drifting lower recently, with the stock down about 10% over the past 3 months and roughly 14% over the past year despite steady revenue and earnings growth. See our latest analysis for Zimmer Biomet Holdings. That slide reflects fading momentum rather than a collapsing business, with the latest $94.14 share price and weak recent share price returns helping explain why the 1 year total shareholder return has drifted noticeably into negative territory. If...
Knee Replacement Surgery Market Analysis Report 2025-2035: Stryker, Zimmer Biomet, B. Braun, and DePuy Synthes Lead Innovations by Continually Innovating and Improving Patient Outcomes
19.11.2025 14:48
Knee replacement surgery effectively addresses severe knee conditions like osteoarthritis, offering pain relief and improved mobility. The procedure sees high demand due to rising osteoarthritis among the aging population, especially as global lifespans increase. Although the surgery significantly enhances life quality, challenges such as high costs and lengthy recovery persist, affecting both patients and healthcare systems. The competitive market witnesses innovation from key players like Stry
Why Does Zimmer Biomet's (ZBH) Innovation Push Coincide With Lowered Growth Guidance?
09.11.2025 06:16
Zimmer Biomet Holdings recently reported mixed third-quarter 2025 results, with US$2,001.4 million in sales and US$230.9 million in net income, alongside revised guidance lowering full-year organic revenue growth expectations due to ongoing challenges in international markets. At the same time, the company has taken steps forward in product innovation, gaining FDA Breakthrough Device Designation for its iodine-treated total hip replacement system and acquiring Monogram Technologies to expand...
Zimmer Biomet Holdings, Inc. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next
08.11.2025 12:48
It's been a mediocre week for Zimmer Biomet Holdings, Inc. ( NYSE:ZBH ) shareholders, with the stock dropping 12% to...
Zimmer Biomet Earnings: What To Look For From ZBH
04.11.2025 03:11
Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting results this Wednesday morning. Here’s what to expect.
Zimmer Biomet Announces FDA Breakthrough Designation for World's First Iodine-Treated Total Hip Replacement System
28.10.2025 11:30
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's first-to-world iodine-treated total hip replacement system. This is the first product in Zimmer Biomet history to receive this designation.
Zimmer Biomet (ZBH): Evaluating Valuation After Recent Share Price Momentum
21.10.2025 01:09
Zimmer Biomet Holdings (ZBH) shares have made steady progress in recent weeks, with the stock climbing 8% over the past month. Investors seem to be weighing the company's fundamentals as it navigates a shifting healthcare landscape. See our latest analysis for Zimmer Biomet Holdings. Zimmer Biomet’s recent 8% weekly share price rally follows a period of steady long-term performance, though its 1-year total shareholder return remains slightly negative at -1.4%. This suggests that investors are...
Zimmer Biomet Q3 Earnings To Highlight Innovation And Growth - Why I Think It's A Buy
12.10.2025 04:24
Zimmer Biomet is undervalued despite recent underperformance, backed by innovation, acquisitions, and strong cash flow. Learn why ZBH stock is a buy.
Zimmer Biomet Launches Two New Foot and Ankle Solutions for Complex Trauma Cases
08.10.2025 11:30
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Paragon 28, a wholly owned subsidiary, today announced the full commercial launch of two innovative solutions for complex foot and ankle trauma to offer surgeons advanced tools to address challenging pilon fractures and hindfoot injuries with precision and efficiency.
2 Safe-and-Steady Stocks on Our Buy List and 1 That Underwhelm
08.10.2025 04:35
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2025 Financial Results
03.10.2025 11:30
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, November 5, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET.
3 Reasons to Avoid ZBH and 1 Stock to Buy Instead
03.10.2025 04:01
Over the past six months, Zimmer Biomet’s stock price fell to $99.17. Shareholders have lost 12% of their capital, which is disappointing considering the S&P 500 has climbed by 24.7%. This might have investors contemplating their next move.
Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures
24.09.2025 12:49
SYK posts 11% sales growth and EPS beat for Q2, driven by Mako robotics and MedSurg strength, but faces cost and margin headwinds.
Does Zimmer Biomet’s Raised Guidance and Lower Tariff Headwinds Strengthen the Bull Case for ZBH?
20.09.2025 12:49
Zimmer Biomet reported better-than-expected Q2 2025 results, with revenues of US$2.08 billion and adjusted EPS of US$2.07, leading management to raise full-year forecasted adjusted EPS to US$8.10–US$8.30 and reduce its anticipated tariff headwinds to about US$40 million. Industry analysts pointed to the company's reduced tariff impact and upwardly revised guidance as factors that set Zimmer Biomet apart among peers in a strong quarter for surgical equipment and consumables. We'll examine how...